Unknown

Dataset Information

0

Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis.


ABSTRACT:

Purpose

To investigate the association between polymorphism rs1061170 (T1277C, Y402H) in age-related macular degeneration (AMD) susceptibility gene Complement Factor H (CFH) and treatment response of neovascular AMD.

Methods

We performed a literature-based meta-analysis including 10 published association studies involving 1,510 patients. Treatments included anti-VEGF (bevacizumab and ranibizumab) or photodynamic therapy. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed- and random-effects models. Q-statistic test was used to assess heterogeneity.

Results

Polymorphism rs1061170 showed a significant summary OR of 1.68 (95% CI, 1.09 to 2.60; P = 0.020; CC versus TT; random-effects) for treatment response of neovascular AMD with heterogeneity of 0.09. In subgroup analysis, rs1061170 was more likely to be a predictor of response to anti-VEGF therapy (P = 0.011). However, heterozygous TC genotype was not associated with altered treatment response (OR = 1.18, 95% CI, 0.95 to 1.47; P = 0.145; fixed-effects). Influence analysis indicated the robustness of our findings.

Conclusions

rs1061170 might be associated with treatment response of neovascular AMD, especially for the anti-VEGF agents. It might be the first meta-analytically confirmed genetic marker predictive for AMD treatment response though a further validation in larger studies is needed.

SUBMITTER: Chen H 

PROVIDER: S-EPMC3419212 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis.

Chen Han H   Yu Ke-Da KD   Xu Ge-Zhi GZ  

PloS one 20120814 8


<h4>Purpose</h4>To investigate the association between polymorphism rs1061170 (T1277C, Y402H) in age-related macular degeneration (AMD) susceptibility gene Complement Factor H (CFH) and treatment response of neovascular AMD.<h4>Methods</h4>We performed a literature-based meta-analysis including 10 published association studies involving 1,510 patients. Treatments included anti-VEGF (bevacizumab and ranibizumab) or photodynamic therapy. Summary odds ratios (ORs) and 95% confidence intervals (CIs)  ...[more]

Similar Datasets

| S-EPMC1941700 | biostudies-literature
| S-EPMC3726372 | biostudies-literature
| S-EPMC3192039 | biostudies-literature
| S-EPMC6301675 | biostudies-literature
| S-EPMC5886461 | biostudies-literature
| S-EPMC2515825 | biostudies-literature
| S-EPMC1226187 | biostudies-literature
| S-EPMC7460693 | biostudies-literature
| S-EPMC4842097 | biostudies-literature
| S-EPMC3880448 | biostudies-other